Purpose: To evaluate local control effects of transcatheter arterial chemoembolization (TACE) using miriplatin and cisplatin (double platinum-lipiodol suspension TACE: [DP-TACE]), and its safety for inoperable hepatocellular carcinoma (HCC). Materials and methods: Between March 2010 and March 2011, 91 HCC cases were treated with superselective DP-TACE. The treatment effect (TE) was determined after 2-3 months of therapy. Adverse events were evaluated using Common Terminology Criteria for Adverse Events v4.0. Results: 37 (40.6%) HCCs showed TE4; 22 (24.2%), TE3; 22 (24.2%), TE2; 10 (11.0%), TE1. Fifty-one HCCs < 30 mm in diameter were TE3+4 and 8 HCCs ≥ 30 mm were TE3+4 (p<0.001). Adverse events were limited to grade 1, 2 or 3 and all cases were transient. Conclusion: The antitumor efficacy of DP-TACE was acceptable.